1. World Health Organization. Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation Geneva, Switzerland: Presented at the World Health Organization ; June 3 5, 1997 ; Publication WHO/NUT/NCD/98.1.
2. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999, 2000. JAMA 2002;288:1723-1727.
3. Wolf AM, Colditz GA. Current estimates of the economic cost of obesity in the United States. Obes Res 1998;6:97-106.
5. Van Gaal LF, Wauters MA, De Leeus IH. The beneficial effect of modest weight loss on cardiovascular risk factors. Int J Obes Relat Metab Disord 1997;21:S5-S9.
6. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 1992;16:397-415.
7. Tremblay A, Doucet E, Imbeault P, Mauriege P, Despres J-P, Richard D. Metabolic fitness in active reduced-obese individuals. Obes Res 1999;7:556-563.
8. Khan LK, Serdula MK, Bowman BA, Williamson DF. Use of prescription weight loss pills among US adults in 1996-1998. Ann Intern Med 2001;134:282-286.
9. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Schaff HV, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-588.
12. American Dietetic Association. Position of the American Dietetic Association: weight management. J Am Diet Assoc 1997;97:71-74.
13. Moloney M. Dietary treatments of obesity. Proc Nutr Soc 2000;59:601-608.
14. Melanson KJ, Dwyer J. In: Stunkard AJ, Wadden TA, editor. Dietary treatment of obesity and overweight: popular diets. Obesity: Theory and Therapy 2000;3rd ed. New York: Raven Press Ltd.
15. Klem M, Wing R, McGuire M, Seagle H, Hill J. A descriptive study of individuals successful at long-term maintenance of substantial weight loss. Am J Clin Nutr 1997;66:239-246.
16. Katzel LI, Bleecker ER, Coleman EG, Rogus EM, Sorkin JD, Goldberg AP. Effects of weight loss vs. aerobic exercise training on risk factors for coronary disease in healthy, obese, middle-aged and older men:a randomized controlled trial. JAMA 1995;274:1915-1921.
17. Rippe JM, Price JM, Hess SA, Kline G, DeMers KA, Freedson P, et al. Improved psychological well-being, quality of life and health practices in moderately overweight women participating in a 12-week structured weight loss program. Obes Res 1998;6:208-218.
18. American College of Sports Medicine. ASCM's Guidelines for Exercise Testing and Prescription 2000;6th ed. Baltimore: Lippincott Williams Wilkins.
19. Perri MG, Nezu AM, McKelvey WF, Shermer RL, Renjilian DA, Viegener BJ. Relapse prevention training and problem-solving therapy in the long-term management of obesity. J Consult Clin Psychol 2001;69:722-726.
20. Klein S. Medical management of obesity. Surg Clin North Am 2001;81:1025-1038.
21. WHO/International Association for the Study of Obesity/International Obesity Task force. The Asia-Pacific perspective: redefining obesity and its treatment 2000.
22. Yanovski SZ, Yanovski JA. Obesity. New Engl J Med 2002;346(8):591-602.
23. Munro JF, MacCuish AC, Wilson EM, Duncan LJ. Comparison of continuous and intermittent anorectic therapy in obesity. BMJ 1968;1:352-354.
24. Cass LJ. Evaluation of phendimetrazine as an appetite suppressant. Can Med Assoc J 1961;84:1114-1116.
25. Smith IG. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract 2001;50:505-512.
26. Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E. Long-term maintenance of weight loss after a very-low-calorie diet:a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 1999;106:179-184.
27. James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Van Gaal LF, et al. Effect of sibutramine on weight maintenance after weight loss:a randomised trial. Lancet 2000;356:2119-2125.
28. Bach DS, Rissanen AM, Mendel CM, Shepherd G, Weinstein SP, Armstrong WF, et al. Absence of cardiac valve dysfunction in obese patients treated with sibutramine. Obes Res 1999;7:363-369.
29. Levine LR, Enas GG, Thompson WL, Byyny RL, Dauer AD, McIlwain HH, et al. Use of fluoxetine, a selective serotoninuptake inhibitor, in the treatment of obesity: a doseresponse study. Int J Obes 1989;13:635-645.
30. Goldstein DJ, Rampey AH Jr, Roback PJ, Wilson MG, Hamilton SH, Tollefson GD, et al. Efficacy and safety of longterm fluoxetine treatment of obesity maximizing success. Obes Res 1995;3:Suppl 4. 481S-490S.
31. Reimherr FW, Cunningham LA, Batey SR, Johnston JA, Ascher JA. A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients. Clin Ther 1998;20:505-516.
32. Gadde KM, Parker CB, Maner LG, Wagner HR 2nd, Logue EJ, Krishnan KR, et al. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obes Res 2001;9:544-551.
33. Anderson JW, Greenway FL, Fujioka K, Gadde KM, McKenney J, O'Neil PM. Bupropion SR enhances weight loss:a 48-week double-blind placebo-controlled trial. Obes Res 2002;10:633-641.
34. Jain AK, Kaplan RA, Gadde KM, Wadden TA, Allison DB, Metz A, et al. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obes Res 2002;10:1049-1056.
35. Picard F, Deshaies Y, Lalonde J, Samson P, Richard D. Topiramate reduces energy and fat gains in lean and obese Zucker rats. Obes Res 2000;8:656-663.
36. Bray G, Klein S, Levy B, et al. Topiramate produces dose-related weight loss in obese patients. The American Diabetes Association Annual Meeting June 15, 2002. Abstract A 1727 - P.
37. Shapira NA, Goldsmith TD, McElroy SL. Treatment of bingeeating disorder with topiramate: a clinical case series. J Clin Psychiatry 2000;61:368-372.
38. Appolinario JC, Coutinho W, Fontenelle L. Topiramate for binge-eating disorder. Am J Psychiatry 2001;158:967-968.
39. Finer N, James WPT, Kopelman PG, Lean MEJ, Williams G. One-year treatment of obesity:a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord 2000;24:306-313.
40. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 2000;9:160-167.
41. Hill JO, Hauptman J, Anderson JW, Fujioka K, O'Neil PM, Aronne LJ, et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting:a 1-y study. Am J Clin Nutr 1999;69:1108-1116.
42. Hauptman JB, Jeunet FS, Hartmann D. Initial studies in humans with the novel gastrointestinal lipase inhibitor(tetrahydrolipstatin). Am J Clin Nutr 1992;55:309S-313S.
43. Scheen AJ, Lefebvre PJ. Pharmacological treatment of obesity: present status. Int J Obes Relat Metab Disord 1999;23:Suppl 1. 47-53.
44. Astrup A, Breum L, Toubro S, Hein P, Quaade F. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial. Int J Obes Relat Metab Disord 1992;16:269-277.
45. Boozer CN, Daly PA, Homel P, Solomon JL, Blanchard D, Meredith T, et al. Herbal ephedra/caffeine for weight loss: a 6-month randomized safety and efficacy trial. Int J Obes Relat Metab Disord 2002;26(5):593-604.
46. Daly PA, Krieger DR, Dulloo AG, Young JB, Landsberg L. Ephedrine, caffeine and aspirin:safety and efficacy for treatment of human obesity. Int J Obes Relat Metab Disord 1993;17:Suppl 1. S73-S78.
47. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000;343(25):1833-1838.
48. Finer N, Bloom SR, Frost GS, Banks LM, Griffiths J. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes:a randomised, double-blind, placebo-controlled study. Diabetes Obes Metab 2000;2:105-112.
49. Fujioka K, Seaton TB, Rowe E. Sibutramine improves glycemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2000;2:175-187.
50. Hollander PA, Elbein SC, Hirsch IB, Kelley D, Hauptman J. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998;21(8):1288-1294.
51. Krejs GJ. Metabolic benefits associated with sibutramine therapy. Int J Obes Relat Metab Disord 2002;26:Suppl 4. S34-S37.
52. Wirth A, Krause J. Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 2001;286:1331-1339.
53. New frontiers in the weight management (XENDOS Study) 2002;mini-symposium by Roche, ICO, Sao Paulo.
54. Kelley DE, Bray GA, Pi-Sunyer FX, Klein S, Hill J, Hollander P. Clinical efficay of orlistat therapy in overweight and obese patietns with insulin-treated type 2 diabetes. Diabetes Care 2002;25:1033-1041.
55. Hauner H. Current pharmacological approaches to the treatment of obesity. Int J Obes Relat Metab Disord 2001;25:Suppl 1. S102-S106.
56. Monteforte MJ, Turkelson CM. Bariatric surgery for the morbid obese. Obes Surg 2000;10:391-401.
57. Brolin RE. Gastric bypass. Surg Clin North Am 2001;81:1077-1095.